Internal Medicine, Hematology & Oncology · Fort Worth, TX
NPI
1871506733
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
500 S Henderson St Ste 200
Fort Worth, TX, 76104
Phone (817) 413-1500
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.1M
100,582 services
Medicare patients, 2024
482
Average age 74
Drug cost, 2024
$4.9M
1,402 prescriptions
Company payments, 2025
$16K
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Harris V Naina was code J9271 (injection, pembrolizumab, 1 mg), 16,300 times for 29 patients. In total Harris V Naina billed 100,582 services in 171 codes, and Medicare paid $2.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-08-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 16,300 | 29 | $44.36 | $723K |
| J9025 Injection, azacitidine, 1 mg | Office | 8,500 | 16 | $0.29 | $2,456 |
| J1453 Injection, fosaprepitant, 1 mg | Office | 8,400 | 36 | $0.11 | $957 |
| J9267 Injection, paclitaxel, 1 mg | Office | 7,024 | 16 | $0.08 | $567 |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 5,135 | 12 | $2.29 | $12K |
| 88185 Surgical Pathology Examination | Office | 1,969 | 51 | $18.41 | $36K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,288 | 68 | $0.09 | $117 |
| J0897 Injection, denosumab, 1 mg | Office | 1,200 | 13 | $20.34 | $24K |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 850 | 40 | $0.26 | $222 |
| 36415 Venipuncture Blood Collection | Office | 698 | 178 | $8.65 | $6,038 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 580 | 38 | $0.70 | $406 |
| 80053 Clinical Chemistry | Office | 557 | 160 | $10.33 | $5,757 |
| 85025 Blood Count | Office | 542 | 164 | $7.61 | $4,125 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 493 | 195 | $12.18 | $6,002 |
| 99215 Office E&M - Established | Office | 398 | 114 | $136.74 | $54K |
By year: 2022 $1.1M for 60,214 services; 2023 $1.1M for 48,261 services; 2024 $2.1M for 100,582 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88185 Surgical Pathology Examination | 1,969 | 51 | $18.41 | $36K |
| 36415 Venipuncture Blood Collection | 698 | 178 | $8.65 | $6,038 |
| 80053 Clinical Chemistry | 557 | 160 | $10.33 | $5,757 |
| 85025 Blood Count | 542 | 164 | $7.61 | $4,125 |
| 82784 Immunoassay | 220 | 45 | $9.11 | $2,005 |
| 83521 Immunoassay | 162 | 39 | $16.93 | $2,742 |
| 85027 Blood Count | 157 | 41 | $6.34 | $995 |
| 85007 Blood Count | 157 | 41 | $3.72 | $584 |
| 83615 Clinical Chemistry | 148 | 66 | $5.92 | $876 |
| 85055 Blood Count | 138 | 34 | $35.03 | $4,834 |
Medicare prescription drug claims, 2024
In 2024, the drug Harris V Naina prescribed most often to Medicare patients was Valacyclovir (Valacyclovir Hcl), with 134 prescriptions and refills. In total Harris V Naina wrote 1,402 Medicare prescriptions that cost $4.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Valacyclovir Valacyclovir Hcl | 134 | 190 | 44 | $5,361 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 90 | 90 | 36 | $2,964 |
| Dexamethasone Generic | 65 | 86 | 29 | $856 |
| Eliquis Apixaban | 56 | 72 | 12 | $43K |
| Revlimid Lenalidomide | 53 | 53 | 13 | $765K |
| Hydroxyurea Generic | 47 | 93 | 13 | $872 |
| Megestrol Acetate Generic | 41 | 42 | 15 | $2,004 |
| Venclexta Venetoclax | 40 | 40 | 18 | $576K |
| Prednisone Generic | 39 | 41 | 17 | $124 |
| Jakafi Ruxolitinib Phosphate | 39 | 39 | Under 11 | $657K |
| Xarelto Rivaroxaban | 38 | 42 | Under 11 | $23K |
| Ondansetron Hcl Generic | 38 | 38 | 19 | $185 |
| Pregabalin Generic | 38 | 40 | Under 11 | $557 |
| Lenalidomide Generic | 34 | 34 | Under 11 | $401K |
| Levofloxacin Generic | 34 | 34 | 21 | $132 |
Brand drugs: 379 claims; generic drugs: 1,023 claims; opioid claims: 144.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Harris V Naina $16K ($16K in general payments such as food, travel and fees) from 18 companies. The largest payer was BeOne Medicines USA, Inc. with $12K.
| Company | Payments | Amount |
|---|---|---|
| BeOne Medicines USA, Inc. ONC | 9 | $12K |
| Janssen Biotech, Inc. JNJ | 3 | $1,844 |
| AstraZeneca Pharmaceuticals LP AZN | 1 | $1,000 |
| Celgene Corporation BMY | 7 | $201 |
| Genzyme Corporation SNY | 3 | $77.45 |
| Abbvie Inc. ABBV | 3 | $67.28 |
| Sobi, Inc SOBI.ST | 2 | $50.28 |
| Karyopharm Therapeutics Inc. KPTI | 2 | $44.43 |
| GlaxoSmithKline, LLC. GSK | 2 | $31.66 |
| Legend Biotech USA Inc. LEGN | 1 | $30.64 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.